IDE-161

Phase 1Small molecule

IIDEAYA Biosciences

IDE-161 is one of 5 small molecule programs targeting Advanced or Metastatic Solid Tumors. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced or Metastatic Solid TumorsActive, not recruiting

Advanced or Metastatic Solid TumorsPhase 1

Active, not recruiting

Competition

Competitive Landscape

5 competitors in Advanced or Metastatic Solid Tumors

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 1

21 2

Vectibix

Amgen

Phase 1

1 3

IDE-161

IIDEAYA Biosciences

Phase 1

1 4

ERAS-601

EErasca, Inc.

Preclinical

2 5

ERAS-007

EErasca, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Active, not recruiting

Advanced or Metastatic Solid Tumors

NCT05787587

Clinical

Trials by Indication[1]

Advanced or Metastatic Solid Tumors1 trial

A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors

Active, not recruiting·IIDEAYA Biosciences·Phase 1·NCT05787587·216 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for IDE-161. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — IDE-161 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for IDE-161. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — IDEAYA Biosciences company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: IIDEAYA Biosciences

IDE-161

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Advanced or Metastatic Solid Tumors1 trial

References

Drug Info

Quick Facts

Related News